Hutchmed (china) Share Discussion Threads

[lauders] 17/9/2019 12:09

Not sure it is CH myself. It is a general lack of confidence after the badly handled HK listing lead-up and then postponment as well as some not so great news from the company. That did little to move the share price when some good news did arrive and now we are in limbo until some good news arrives and the market views HCM more favourably. Agree the spread is a disgrace post share adjustment! A narrower spread would help the investment case here.

[thornyone] 17/9/2019 09:26

I think Mr CH is the problem. He may be a good presenter, but he is secretive and vague about test results. Shareholders are a nuisance for him. His main concern is long term security. One can only hope that test results in the short-term are good.

[yidarmytom] 17/9/2019 06:42

GWP have done very well and have a proper valuation on NASDAQ, it also seems the London market cannot value smaller growing Biotechs correctly. I hope the HK listing gets resurrected prior to the end of the year now the political situation has stabilised a little. Other Biotechs continue to list there.

[steeplejack] 16/9/2019 21:18

GW pharmaceuticals is an obvious precedent .Funds were raised via Nasdaq and the company subsequently decided to delist from AIM.

[dbadvn] 16/9/2019 18:05

Don't forget stock market is a sentiment machine in the short term and a weighing machine in the long term.

Of course in the long term we are all dead ….

I agree that the AIM listing is pointless. Question, what would happen to AIM listed shares if the listing is dropped . I assume we would be offered the choice of ADR or HK listed shares after the ipo? Must be precedent here.

[steeplejack] 16/9/2019 17:53

Yes,we've discussed this before and I think you're right.The AIM spread might not put off the long term investor but its a reflection of very low volumes.I'd prefer the company to step up to a main board LSE listing.Unlikely.

[nerdofsteel] 16/9/2019 17:32

Despite all the great progress the last 2.5 years of growth has been wiped out and we are back to March 2017.

and to the point about the spread, it really does not make it investible for short to medium term trades and holders. The share split has done nothing here, volumes are very low.

If I were the Company I think I'd look to get the HK IPO off the ground, then maintain that and NASDAQ, and ditch AIM/London as there is no point being listed here any longer

[steeplejack] 16/9/2019 16:56

Article on today's FT on front page headed "Chinese companies shed $40 bn in global assets as US divestments soar".I'm wondering whether this has affected sentiment a tad today.No reason why it should ,of course,but sentiment can be fickle.Lost all recent upside in one foul swoop.

[nhb001] 16/9/2019 14:22

7% spread. That share split really worked a treat.

[nerdofsteel] 16/9/2019 07:12

I do hope we get a better reaction with the Surufatinib NDA and subsequent launch than we did with Fruquintinib, when there was essentially no reaction!

This time of course Surufatinib is wholly owned, so that may help.

[nhb001] 11/9/2019 16:34

Thanks for posting that link NoS. It was a good listen.

[nerdofsteel] 11/9/2019 13:15

New Trinity Delta Note

[nerdofsteel] 11/9/2019 07:57

Brad Loncar (manager China Biotech ETF on NASDAQ) is a man with close contacts and a great network - he clearly has insight that HK Biotech IPO's will start to ramp up again in November

[nerdofsteel] 11/9/2019 07:57

Brad Loncar (manager China Biotech ETF on NASDAQ) is a man with close contacts and a great network - he clearly has insight that HK Biotech IPO's will start to ramp up again in November

[nerdofsteel] 09/9/2019 09:52

One has to hope that the short sellers note and attack on BGNE does not overspill to Chi-Med. There is no reason why it should but you know what the market is like - nonsensical most of the time.

One also has to hope that the ditching of the extradition bill will calm things enough for Companies such as Chi-Med to resurrect their HK IPO plans.

[saiyang2019] 09/9/2019 09:27

Be looking for any changes after September.

[nerdofsteel] 05/9/2019 09:57

It is interesting that a number of Biotech's are still proceeding with their IPO's in HK, and activity appears to be increasing again. Now that Carrie Lam's extradition Bill is being shelved, hopefully this will boost confidence in the region and in HK's reputation as a great place to go public and raise capital.



Immunotech Biopharm & Pharmaron are two that have applied for listings in the last couple of weeks alone

[its the oxman] 02/9/2019 11:23

Expecting this to spike higher , probably on an update , but just a question of when, I hope.

[steeplejack] 27/8/2019 23:24

Months high in the US and against the run of play.Encouraging.

[nerdofsteel] 21/8/2019 17:19

Having been buying for many years since the 250p days (25p equivalent), and looking at my trading history, my average buy price in the last 3 years is an equivalent of just under 400p.

The peak price was £5.60 and that is close to what Trinity Delta value the Business at (£5.93) but less that Edison's £6.99 per share.

I am still bemused we are at the same price as 26 months ago, despite 1 drug launched, and another NDA imminent, despite some setbacks. My own view is this could still be a $20bn Company in the next 10 years.

[sportii] 21/8/2019 09:36

Thanks sj for the info.
5% is big percentage of stocks. Following the recent decline in sp, this is good news.
Hopefully, the savannah study, in collaboration with AZN, proves to be therapeutically effective.